NasdaqGS:CGONBiotechs
CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings
What CG Oncology’s Latest Earnings Tell You About the Business
CG Oncology (CGON) recently posted second quarter and first half 2026 results, giving investors fresh detail on how revenue and losses are tracking for this late stage bladder cancer focused biotech.
For the quarter ended June 30, 2026, CG Oncology reported revenue of US$1.16 million. The company recorded a net loss of US$79.06 million and a basic loss per share from continuing operations of US$0.90.
For the first six months of...